Crestline Management LP Grows Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Crestline Management LP raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 114.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 295,354 shares of the biopharmaceutical company's stock after purchasing an additional 157,366 shares during the period. Crestline Management LP owned 0.45% of Celldex Therapeutics worth $7,464,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC increased its position in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 878 shares during the period. Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics in the fourth quarter worth about $81,000. KBC Group NV boosted its position in Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock valued at $94,000 after buying an additional 1,647 shares in the last quarter. AlphaQuest LLC grew its position in Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after acquiring an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in shares of Celldex Therapeutics during the fourth quarter worth about $121,000.

Celldex Therapeutics Stock Down 6.1 %

NASDAQ:CLDX traded down $1.19 during trading hours on Friday, reaching $18.33. The company had a trading volume of 1,001,538 shares, compared to its average volume of 889,846. The business's 50-day simple moving average is $18.99 and its two-hundred day simple moving average is $22.84. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -7.13 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. As a group, equities analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Canaccord Genuity Group began coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They set a "buy" rating and a $64.00 price target for the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. The Goldman Sachs Group lowered their price objective on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research report on Friday. UBS Group reduced their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Friday. Finally, Morgan Stanley lowered their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Friday. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Celldex Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $53.90.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.